TRIM21 and systemic lupus erythematosus: Clinically, the presence of anti‐TRIM21 autoantibodies correlates with reduced TRIM21 protein expression, elevated IFN‐β levels, and increased immunoglobulin subclasses, highlighting their role as potential biomarkers for immune dysregulation in SLE (Figure 5B) [312].